Image-Guided Radioiodide Therapy of Medullary Thyroid Cancer After Carcinoembryonic Antigen Promoter-Targeted Sodium Iodide Symporter Gene Expression

2007 ◽  
Vol 18 (10) ◽  
pp. 916-924 ◽  
Author(s):  
Christine Spitzweg ◽  
Claire H. Baker ◽  
Elizabeth R. Bergert ◽  
M.K. O'Connor ◽  
John C. Morris
Keyword(s):  
Gene Expression ◽  
Thyroid Cancer ◽  
Carcinoembryonic Antigen ◽  
Sodium Iodide ◽  
Medullary Thyroid Cancer ◽  
Sodium Iodide Symporter ◽  
Medullary Thyroid ◽  
Image Guided ◽  
Radioiodide Therapy

scholarly journals Autophagy activity is associated with membranous sodium iodide symporter expression and clinical response to radioiodine therapy in non-medullary thyroid cancer

Autophagy ◽  
2016 ◽  
Vol 12 (7) ◽  
pp. 1195-1205 ◽  
Author(s):  
Theo S. Plantinga ◽  
Marika H. Tesselaar ◽  
Hans Morreau ◽  
Eleonora P. M. Corssmit ◽  
Brigith K. Willemsen ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Clinical Response ◽  
Sodium Iodide ◽  
Medullary Thyroid Cancer ◽  
Radioiodine Therapy ◽  
Sodium Iodide Symporter ◽  
Medullary Thyroid ◽  
Autophagy Activity

scholarly journals The RET Kinase Inhibitor NVP-AST487 Blocks Growth and Calcitonin Gene Expression through Distinct Mechanisms in Medullary Thyroid Cancer Cells

2007 ◽  
Vol 67 (14) ◽  
pp. 6956-6964 ◽  
Author(s):  
Nagako Akeno-Stuart ◽  
Michelle Croyle ◽  
Jeffrey A. Knauf ◽  
Roberta Malaguarnera ◽  
Donata Vitagliano ◽  
...  
Keyword(s):  
Gene Expression ◽  
Thyroid Cancer ◽  
Cancer Cells ◽  
Medullary Thyroid Cancer ◽  
Kinase Inhibitor ◽  
Medullary Thyroid ◽  
Calcitonin Gene ◽  
Thyroid Cancer Cells

scholarly journals Induction of Thyroid Gene Expression and Radioiodine Uptake in Thyroid Cancer Cells by Targeting Major Signaling Pathways

2010 ◽  
Vol 95 (2) ◽  
pp. 820-828 ◽  
Author(s):  
Peng Hou ◽  
Ermal Bojdani ◽  
Mingzhao Xing
Keyword(s):  
Gene Expression ◽  
Thyroid Cancer ◽  
Cancer Cells ◽  
Signaling Pathways ◽  
Histone Deacetylase ◽  
Sodium Iodide ◽  
Therapeutic Potential ◽  
Sodium Iodide Symporter ◽  
Thyroid Cells ◽  
Thyroid Cancer Cells

Abstract Context: Radioiodine ablation is commonly used to treat thyroid cancer, but a major challenge is often the loss of radioiodine avidity of the cancer caused by aberrant silencing of iodide-handling genes. Objectives: This study was conducted to test the therapeutic potential of targeting the aberrantly activated MAPK and PI3K/Akt/mTOR pathways and histone deacetylase to restore radioiodine avidity in thyroid cancer cells. Experimental Design: We tested the effects of specific inhibitors targeting these pathways/molecules that had established clinical applicability, including the MAPK kinase inhibitor RDEA119, mTOR inhibitor temsirolimus, Akt inhibitor perifosine, and histone deacetylase inhibitor SAHA, individually or in combinations, on the expression of iodide-handling genes and radioiodide uptake in a large panel of thyroid cancer cell lines. Results: The expression of a large number of iodide-handling genes could be restored, particularly the sodium/iodide symporter, TSH receptor, and thyroperoxidase, by treating cells with these inhibitors. The effect was particularly robust and synergistic when combinations of inhibitors containing SAHA were used. Robust expression of sodium/iodide symporter in the cell membrane, which plays the most important role in iodide uptake in thyroid cells, was confirmed by immunofluorescent microscopy. Radioiodide uptake by cells was correspondingly induced under these conditions. Thyroid gene expression and radioiodide uptake could both be further enhanced by TSH. Conclusions: Targeting major signaling pathways could restore thyroid gene expression and radioiodide uptake in thyroid cancer cells. Further studies are warranted to test this therapeutic potential in restoring radioiodine avidity of thyroid cancer cells for effective ablation treatment.

Improved detection of medullary thyroid cancer with radiolabeled antibodies to carcinoembryonic antigen.

1996 ◽  
Vol 14 (4) ◽  
pp. 1209-1217 ◽  
Author(s):  
M Juweid ◽  
R M Sharkey ◽  
T Behr ◽  
L C Swayne ◽  
A D Rubin ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Carcinoembryonic Antigen ◽  
Medullary Thyroid Cancer ◽  
Imaging Studies ◽  
Medullary Thyroid ◽  
Primary Surgery ◽  
Occult Disease ◽  
Iodine 131 ◽  
Iodine 123 ◽  
Magnetic Resonance Imaging Mri

PURPOSE This investigation was undertaken to assess the targeting of established and occult medullary thyroid cancer (MTC) with radiolabeled monoclonal antibodies (MAbs) reactive with carcinoembryonic antigen (CEA). PATIENTS AND METHODS Twenty-six assessable patients with known (n = 17) or occult (n = 9) MTC were studied with radiolabeled anti-CEA MAbs. Scintigraphic images were collected to determine targeting of tumor lesions. RESULTS The targeting results of technetium 99m (99mTc)-,iodine 123 (123I)-, and iodine 131 (131I)-labeled anti-CEA antibodies (all directed against the same epitope of CEA) indicated that all these reagents were capable of detecting established and occult MTC. The sensitivity for detection of known sites of disease ranged from 76% to 100% for the various anti-CEA MAbs used, when compared with computed tomography (CT), magnetic resonance imaging (MRI), bone scan, or other imaging modalities. Moreover, the antibody scan was positive in seven of nine patients with occult disease (patients with negative conventional imaging studies, but who had elevated calcitonin and/or CEA levels). Three of seven patients underwent surgery and the disease was confirmed by histopathology in all three. CONCLUSION Anti-CEA MAbs are excellent agents for imaging recurrent, residual, or metastatic MTC. The high lesion sensitivity in patients with known lesions, combined with the ability to detect disease, may make these agents ideal for staging patients, monitoring disease pretherapy or posttherapy, and especially for evaluating patients with recurrent or persistent hypercalcitonemia or CEA elevations after primary surgery. Analogous to radioiodine in the evaluation of patients with differentiated thyroid cancer, radiolabeled anti-CEA MAbs may achieve a similar role in diagnosing and monitoring patients with MTC.

Sign in / Sign up

Export Citation Format

Share Document